Literature DB >> 1176889

Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation.

B S Joseph, M B Oldstone.   

Abstract

Upon the addition of antibody to measles virus, measles virus antigens expressed on the surface of infected cells can be modulated from the cell's membrane in vitro. Removal of measles virus antigens from the surface of cells occurs relatively rapidly and is accompanied by a parallel reduction in the ability of antibody and complement to lyse these cells. Modulation of surface viral antigens can occur in the absence of cap formation and is fully reversible once measles virus antibodies are removed from culture medium. Protracted exposure of acutely infected cells to measles virus antibodies results in a population of cells that exhibit normal cytomorphology and growth behavior. These cells continue to express measles virus antigens internally, but not at the cell surface, and are refractory to immune lysis. Once antiviral antibody is removed, measles virus antigens again appear on the cell surface, giant cell and syncytial formation occur, and cell death follows. These observations may explain the persistence of virus in spite of a vigorous host antiviral immune response in certain chronic infections of man.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1176889      PMCID: PMC2189944          DOI: 10.1084/jem.142.4.864

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Studies on the effect of specific antisera on the metabolism of cellular antigens. II. The synthesis and degradation of TL antigens of mouse cells in the presence of TL antiserum.

Authors:  A Yu; E P Cohen
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

2.  Maintenance of latent herpetic infection: an apparent role for anti-viral IgG.

Authors:  J G Stevens; M L Cook
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  Persistent infection of cells in culture by measles virus. I. Development and characteristics of HeLa sublines persistently infected with complete virus.

Authors:  R Rustigian
Journal:  J Bacteriol       Date:  1966-12       Impact factor: 3.490

5.  Fate of HL-A antigens and antibodies at the lymphocyte surface.

Authors:  S E Cullen; D Bernoco; A O Carbonara; H Jacot-Guillarmod; G Trinchieri; R Ceppellini
Journal:  Transplant Proc       Date:  1973-12       Impact factor: 1.066

6.  Modulation of TL (thymus-leukemia) antigens by Fab-fragments of TL antibody.

Authors:  M E Lamm; E A Boyse; L J Old; B Lisowska-Bernstein; E Stockert
Journal:  J Immunol       Date:  1968-07       Impact factor: 5.422

7.  Measles as an index of immunological function.

Authors:  F M Burnet
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

8.  Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy.

Authors:  L Horta-Barbosa; D A Fuccillo; J L Sever; W Zeman
Journal:  Nature       Date:  1969-03-08       Impact factor: 49.962

9.  The effect of capping H-2 antigens on the susceptibility of target cells to humoral and T cell-mediated lysis.

Authors:  M Ekidin; C S Henney
Journal:  Nat New Biol       Date:  1973-11-14

10.  Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro.

Authors:  L J Old; E Stockert; E A Boyse; J H Kim
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  50 in total

1.  Neutralizing anti-gH antibody of Varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency.

Authors:  Kimiyasu Shiraki; Tohru Daikoku; Masaya Takemoto; Yoshihiro Yoshida; Kazuhiro Suzuki; Yasushi Akahori; Toshiomi Okuno; Yoshikazu Kurosawa; Yoshizo Asano
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Cell-mediated immunity to varicella-zoster virus measured by virus inactivation: mechanism and blocking of the reaction by specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

Review 3.  Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals.

Authors:  Sallie R Permar; Diane E Griffin; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2006-04

4.  Editorial: High-titre hepatitis B immune globulin.

Authors: 
Journal:  Br Med J       Date:  1976-01-31

5.  Viral spread in the presence of neutralizing antibody: mechanisms of persistence in foamy virus infection.

Authors:  J J Hooks; W Burns; K Hayashi; S Geis; A L Notkins
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

6.  Fate of antigen in xenotransplantation: implications for acute vascular rejection and accommodation.

Authors:  W Parker; Z E Holzknecht; A Song; B A Blocher; M Bustos; K J Reissner; M L Everett; J L Platt
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

7.  Persistent infection of tissue culture cells by RNA viruses.

Authors:  R K Rima; S J Martin
Journal:  Med Microbiol Immunol       Date:  1976-06-01       Impact factor: 3.402

8.  Demonstration of T-cell and K-cell cytotoxicity against measles-infected cells in normal subjects, multiple sclerosis and subacute sclerosing panencephalitis.

Authors:  P W Ewan; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

9.  Persistence of infectious Friend virus in spleens of mice after spontaneous recovery from virus-induced erythroleukemia.

Authors:  B Chesebro; M Bloom; K Wehrly; J Nishio
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

10.  Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias.

Authors:  M Bertini; G Galetto; P M Comoglio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.